{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062077","form_type":"8-K","ticker":"ADPT","cik":"0001478320","company_name":"Adaptive Biotechnologies Corp","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.197171+00:00","generated_at":"2026-06-08T06:31:08.914741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adaptive Biotechnologies Q3 revenue down 21% to $37.9M; launches strategic review with Goldman Sachs","bullets":["Q3 2023 revenue $37.9M, down 21% YoY; net loss $50.3M vs $45.3M; Adjusted EBITDA loss $29.8M vs $25.9M.","MRD revenue $24.7M (+24% YoY); Immune Medicine revenue $13.3M (-52% YoY); clonoSEQ test volume +56% to 15,072.","Strategic review of MRD and Immune Medicine businesses underway with Goldman Sachs to maximize shareholder value.","Full-year 2023 guidance: MRD revenue $100-105M; total operating expenses ~$375M; Immune Medicine revenue guidance removed.","Discovered novel multiple sclerosis target, validating autoimmune target discovery approach."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062077","json":"https://secwatch.observer/filing/0000950170-23-062077.json","markdown":"https://secwatch.observer/filing/0000950170-23-062077.md","text":"https://secwatch.observer/filing/0000950170-23-062077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023062077/0000950170-23-062077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023062077/adpt-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T06:31:08.914741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"356b506e05e3902d6e8382bbe586316fd9da9b3e","claim":"Adaptive Biotechnologies Corp reported the quarter ended September 30, 2023 results: revenue $37.9 million, net income $50.3 million. Guidance reaffirmed.","evidence_excerpt":"Revenue was $37.9 million for the quarter ended September 30, 2023, representing a 21% decrease from the third quarter in the prior year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1478320/000095017023062077/0000950170-23-062077-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Revenue","value":"$37.9 million"},{"label":"Net income","value":"$50.3 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}